医薬品開発段階の品質管理<br>Quality by Design for Biopharmaceuticals : Principles and Case Studies (Wiley Series in Biotechnology and Bioengineering)

個数:
電子版価格
¥21,731
  • 電子版あり
  • ポイントキャンペーン

医薬品開発段階の品質管理
Quality by Design for Biopharmaceuticals : Principles and Case Studies (Wiley Series in Biotechnology and Bioengineering)

  • ウェブストア価格 ¥34,054(本体¥30,959)
  • Wiley-Interscience(2009/06発売)
  • 外貨定価 US$ 166.95
  • 読書週間 ポイント2倍キャンペーン 対象商品(~11/9)
  • ポイント 618pt
  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 288 p.
  • 言語 ENG
  • 商品コード 9780470282335
  • DDC分類 615.19

基本説明

Provides an in-depth understanding of the underlying concepts of Quality by Design (QbD) and the practical aspects of the implementation of QbD in biopharmaceutical manufacturing.

Full Description

The concepts, applications, and practical issues of Quality by Design Quality by Design (QbD) is a new framework currently being implemented by the FDA, as well as EU and Japanese regulatory agencies, to ensure better understanding of the process so as to yield a consistent and high-quality pharmaceutical product. QbD breaks from past approaches in assuming that drug quality cannot be tested into products; rather, it must be built into every step of the product creation process.

Quality by Design: Perspectives and Case Studies presents the first systematic approach to QbD in the biotech industry. A comprehensive resource, it combines an in-depth explanation of basic concepts with real-life case studies that illustrate the practical aspects of QbD implementation.

In this single source, leading authorities from the biotechnology industry and the FDA discuss such topics as:



The understanding and development of the product's critical quality attributes (CQA)
Development of the design space for a manufacturing process
How to employ QbD to design a formulation process
Raw material analysis and control strategy for QbD
Process Analytical Technology (PAT) and how it relates to QbD
Relevant PAT tools and applications for the pharmaceutical industry
The uses of risk assessment and management in QbD
Filing QbD information in regulatory documents
The application of multivariate data analysis (MVDA) to QbD

Filled with vivid case studies that illustrate QbD at work in companies today, Quality by Design is a core reference for scientists in the biopharmaceutical industry, regulatory agencies, and students.

Contents

Foreword xiii Preface xv

Preface to the Wiley Series on Biotechnology and Related Topics xvii

Contributors xix

1 QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS 1
Rohin Mhatre and Anurag S. Rathore

1.1 Introduction 1

1.2 Critical Quality Attributes 2

1.3 An Overview of Design Space 3

1.4 Raw Materials and their Impact on QbD 4

1.5 Process Analytical Technology 4

1.6 The Utility of Design Space and QbD 5

1.7 Conclusions 7

2 CONSIDERATIONS FOR BIOTECHNOLOGY PRODUCT QUALITY BY DESIGN 9
Steven Kozlowski and Patrick Swann

2.1 Introduction 9

2.2 Quality by Design 10

2.3 Relevant Product Attributes 11

2.4 Manufacturing Process 14

2.5 Developing a Design Space 18

2.6 Uncertainty and Complexity 22

2.7 Future Horizons 23

2.8 QbD Submission Thoughts 25

2.9 Implementation Plans 26

2.10 Summary 27

3 MOLECULAR DESIGN OF RECOMBINANT MALARIA VACCINES EXPRESSED BY Pichia pastoris 31
David L. Narum

3.1 Introduction 31

3.2 The Malaria Genome and Proteome 34

3.3 Expression of Two Malaria Antigens in P. pastoris 34

3.4 Summary 46

4 USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES 53
Mark A Schenerman, Milton J. Axley, Cynthia N. Oliver, Kripa Ram, and Gail F. Wasserman

4.1 Introduction 53

4.2 Examples of Criticality Determination 60

4.3 Conclusion 81

5 CASE STUDY ON DEFINITION OF PROCESS DESIGN SPACE FOR A MICROBIAL FERMENTATION STEP 85
Pim van Hoek, Jean Harms, Xiangyang Wang, and Anurag S. Rathore

5.1 Introduction 85

5.2 Approach Toward Process Characterization 87

5.3 Risk Analysis 88

5.4 Small-Scale Model Development and Qualification 89

5.5 Design of Experiment Studies 94

5.6 Worst Case Studies 96

5.7 Definition of Design Space 99

5.8 Definition of Validation Acceptance Limits 103

5.9 Regulatory Filing, Process Monitoring, and Postapproval Changes 106

6 APPLICATION OF QbD PRINCIPLES TO TANGENTIAL FLOW FILTRATION OPERATIONS 111
Peter K. Watler and John Rozembersky

6.1 Introduction 111

6.2 Applications of TFF in Biotechnology 113

6.3 Tangential Flow Filtration Operating Principles 113

6.4 TFF Design Objectives 115

6.5 Membrane Selection 115

6.6 TFF Operating Parameter Design 118

6.7 TFF Diafiltration Operating Mode Design 122

6.8 Summary 125

7 APPLICATIONS OF DESIGN SPACE FOR BIOPHARMACEUTICAL PURIFICATION PROCESSES 127
Douglas J. Cecchini

7.1 Introduction 127

7.2 Establishing Design Space for Purification Processes during Process Development 128

7.3 Applications of Design Space 131

7.4 Cell Harvest and Product Capture Steps 131

7.5 Protein A Capture Column 136

7.6 Hydrophobic Interaction Chromatography 137

7.7 Anion Exchange Chromatography 138

7.8 Summary 141

8 VIRAL CLEARANCE: A STRATEGY FOR QUALITY BY DESIGN AND THE DESIGN SPACE 143
Gail Sofer and Jeffrey Carter

8.1 Introduction 143

8.2 Current and Future Approaches to Virus Clearance Characterization 143

8.3 Benefits of Applying Design Space Principles to Virus Clearance 144

8.4 Technical Limitations Related to Adoption of QdB/Design Space Concepts in Virus Clearance 145

8.5 Developing a Virus Clearance Design Space 148

8.6 Staying in the Design Space 156

8.7 Conclusion 157

9 APPLICATION OF QUALITY BY DESIGN AND RISK ASSESSMENT PRINCIPLES FOR THE DEVELOPMENT OF FORMULATION DESIGN SPACE 161
Kingman Ng and Natarajan Rajagopalan

9.1 Introduction 161

9.2 Quality by Design (QbD) Approach 162

9.3 Target Product Profile (TPP) 163

9.4 Molecular Degradation Characterization 164

9.5 Active Pharmaceutical Ingredient (API) Critical Properties 166

9.6 Preformulation Characterization 167

9.7 Initial Formulation Risk Assessments 168

9.8 Formulation Optimization and Design Space 169

9.9 Selection of Solution Formulation Composition 171

9.10 Summary 173

10 APPLICATION OF QbD PRINCIPLES TO BIOLOGICS PRODUCT: FORMULATION AND PROCESS DEVELOPMENT 175
Satish K. Singh, Carol F. Kirchhoff, and Amit Banerjee

10.1 Introduction: QbD in Biologics Product Development 175

10.2 Risk Assessment Process 177

10.3 Examples 178

10.4 Conclusions 191

11 QbD FOR RAW MATERIALS 193
Maureen Lanan

11.1 Introduction 193

11.2 Background 194

11.3 Current Practice for Raw Materials 195

11.4 QbD in Development 195

11.5 QbD in manufacturing 196

11.6 QbD for organizations 197

11.7 Tests Available 197

11.8 Conclusions and Future Prospects 207

12 PAT TOOLS FOR BIOLOGICS: CONSIDERATIONS AND CHALLENGES 211
Michael Molony and Cenk Undey

12.1 Introduction 211

12.2 Cell Culture and Fermentation PAT Tools 214

12.3 Purification PAT Tools 223

12.4 Formulation PAT Tools 228

12.5 PAT Tools for Bioprocess Starting Materials, Defined Media, and Complex Raw Materials 230

12.6 Chemometrics and Advanced Process Control Tools 232

12.7 The power of PLS and PCA 233

12.8 "Relevant Time"Column Integrity Monitoring (Moments Analysis versus HETP) 240

12.9 Challenges for Implementation of PAT Tools 244

12.10 Future PAT Tools 247

13 EVOLUTION AND INTEGRATION OF QUALITY BY DESIGN AND PROCESS ANALYTICAL TECHNOLOGY 255
Duncan Low and Joseph Phillips

13.1 Introduction 255

13.2 Evolution of PAT and Quality by Design (QbD): Emerging Guidelines and Standards 256

13.3 Process Analytical Technology (PAT) 261

13.4 Quality by Design 263

13.5 Implementing QbD and PAT 266

13.6 Conclusions 282

Acknowledgments 283

References 283

Index 287

最近チェックした商品